GRI Bio discusses positive Phase 2a IPF data for GRI-0621
Apr 21, 2026
GRI Bio discussed positive Phase 2a idiopathic pulmonary fibrosis data for GRI-0621, highlighting biomarker results indicating improvements in fibrosis and lung repair.
News Related to Idiopathic Pulmonary Fibrosis
Related coverage linked through entity extraction aliases.
FDA Grants Orphan Drug Designation to Nuformix's Pulmonary Fibrosis Treatment
Apr 03, 2026
The FDA has granted orphan drug designation to Nuformix PLC's tranilast lysate candidate for treating idiopathic pulmonary fibrosis. The designation provides regulatory incentives including potential market exclusivity in the US. Nuformix is a London-based developer focused on fibrosis and oncology treatments.
Deupirfenidone Advances to Phase 3 Trial for Idiopathic Pulmonary Fibrosis
Mar 21, 2026
Deupirfenidone, a deuterated form of pirfenidone, is set to be tested in a phase 3 trial this year after successful phase 2b results. The FDA and European Commission have granted orphan drug designation to support its late-stage development.
Bristol Myers Squibb Growth Portfolio Offsets Legacy Drug Declines in 2025
Mar 03, 2026
Bristol Myers Squibb's growth portfolio increased 17% in 2025, partially offsetting a 15% decline in legacy products facing generic competition. The company's stock gained 11.4% in the past month on strong fourth-quarter results.
Insmed Reports Strong 2025 Results, FDA Grants Orphan Drug Status to Treprostinil Palmitil
Feb 28, 2026
Insmed reported total revenues of $606.4 million for 2025, with ARIKAYCE growing 19% annually. The FDA granted orphan drug designation to treprostinil palmitil for pulmonary arterial hypertension treatment in January 2026.
AbbVie Advances Clinical Pipeline With IPF and Aesthetics Trial Updates
Feb 20, 2026
AbbVie reported progress on two clinical studies: a Phase 2a trial of ABBV-142 for idiopathic pulmonary fibrosis now recruiting patients, and completion of a JUVÉDERM VOLITE study for facial skin quality improvement.
Deupirfenidone Receives Orphan Drug Designation from FDA and European Commission for IPF
Feb 20, 2026
PureTech Health announced that deupirfenidone has received Orphan Drug Designation from both the U.S. FDA and European Commission for idiopathic pulmonary fibrosis, with a Phase 3 trial planned for the first half of 2026.
PureTech's Deupirfenidone Receives FDA and EU Orphan Drug Designation for IPF
Feb 20, 2026
PureTech Health's deupirfenidone has received Orphan Drug Designation from both the U.S. FDA and European Commission for treating idiopathic pulmonary fibrosis, a rare and fatal lung disease. Phase 2b trial results showed superior efficacy compared to existing therapies.
Three Clinical Trial Pipeline Reports Track Progress in Prostate Cancer, NK Cells, and Lung Diseases
Feb 15, 2026
DelveInsight releases three separate pipeline reports covering metastatic prostate cancer (80+ companies, 85+ drugs), iPSC-derived NK cells (12+ companies, 15+ drugs), and interstitial lung diseases (120+ companies, 120+ drugs), highlighting recent regulatory approvals, trial launches, and emerging therapies.
AI Adoption in Clinical Trials Focuses on Operations, Drug Discovery, and Patient Engagement
Dec 29, 2025
Artificial intelligence emerged as the dominant topic in clinical research during 2025, with applications spanning operational efficiency, drug discovery, and patient recruitment, though no AI-discovered drug has yet achieved FDA marketing approval.